NASDAQ:DMAC - DiaMedica Therapeutics Stock Price, Forecast & News

DiaMedica Therapeutics' stock was trading at $4.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, DMAC stock has decreased by 29.8% and is now trading at $2.81. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DiaMedica Therapeutics.

DiaMedica Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for DiaMedica Therapeutics.

DiaMedica Therapeutics Inc (NASDAQ:DMAC) posted its quarterly earnings results on Monday, March, 23rd. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.04. View DiaMedica Therapeutics' earnings history.

2 analysts have issued 12-month price targets for DiaMedica Therapeutics' shares. Their forecasts range from $8.00 to $11.00. On average, they anticipate DiaMedica Therapeutics' stock price to reach $9.50 in the next year. This suggests a possible upside of 238.1% from the stock's current price. View analysts' price targets for DiaMedica Therapeutics.

News stories about DMAC stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. DiaMedica Therapeutics earned a news impact score of -3.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutDiaMedica Therapeutics.

DiaMedica Therapeutics saw a decline in short interest in March. As of March 13th, there was short interest totaling 3,700 shares, a decline of 30.2% from the February 27th total of 5,300 shares. Based on an average trading volume of 40,900 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the shares of the stock are short sold. View DiaMedica Therapeutics' Current Options Chain.

Some companies that are related to DiaMedica Therapeutics include Paratek Pharmaceuticals (PRTK), Fortress Biotech (FBIO), Newron Pharmaceuticals (NWPHF), vTv Therapeutics (VTVT), Avenue Therapeutics (ATXI), Helix Biopharma (HBPCF), TAIWAN LIPOSOME/S (TLC), Savara (SVRA), Theratechnologies (THTX), Galectin Therapeutics (GALT), Affimed (AFMD), Neptune Wellness Solutions (NEPT), OASMIA PHARMACE/ADR (OASM), Obseva (OBSV) and Mustang Bio (MBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include Inovio Pharmaceuticals (INO), vTv Therapeutics (VTVT), Agile Therapeutics (AGRX), Amarin (AMRN), Co-Diagnostics (CODX), Crispr Therapeutics (CRSP), Oncolytics Biotech (ONCY), Seelos Therapeutics (SEEL), VBI Vaccines (VBIV) and Vaxart (VXRT).

(DMAC) raised $18 million in an initial public offering on Friday, December 7th 2018. The company issued 4,000,000 shares at a price of $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

DiaMedica Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.15%) and Blair William & Co. IL (0.08%). Company insiders that own DiaMedica Therapeutics stock include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen. View institutional ownership trends for DiaMedica Therapeutics.

DMAC stock was acquired by a variety of institutional investors in the last quarter, including Blair William & Co. IL, and Geode Capital Management LLC. Company insiders that have bought DiaMedica Therapeutics stock in the last two years include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik, and Scott Kellen. View insider buying and selling activity for DiaMedica Therapeutics.

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DMAC stock can currently be purchased for approximately $2.81.

DiaMedica Therapeutics has a market capitalization of $33.61 million and generates $500,000.00 in revenue each year. The company earns $-5,730,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. DiaMedica Therapeutics employs 9 workers across the globe. View additional information about DiaMedica Therapeutics.

The official website for DiaMedica Therapeutics is http://www.diamedica.com/.

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at 763-312-6755 or via email at [email protected]